Fish oil is one of the most popular supplements in the United States, taken daily by roughly one in five adults who believe omega-3 fatty acids protect the heart and sharpen the brain. But a peer-reviewed study published in Cell Reports in early 2026 complicates that picture for a specific and sizable group: people who have suffered repeated concussions. Researchers at the Medical University of South Carolina found that eicosapentaenoic acid, or EPA, a primary omega-3 in most fish oil capsules, disrupted blood vessel repair in the brain after repeated mild traumatic brain injuries in mice, with downstream changes resembling those seen in chronic traumatic encephalopathy, or CTE.
The findings do not apply to everyone. But for contact-sport athletes, some military veterans, and others with a history of head trauma, they raise a pointed question: Could a supplement taken for protection actually be interfering with recovery?
What the mouse study actually showed
The central experiment, led by researchers at MUSC, used mouse models of repeated mild traumatic brain injury to test how EPA-enriched diets affected the brain’s ability to heal. The results, published in Cell Reports, showed that EPA altered the way cerebrovascular cells metabolize energy after injury. Instead of shifting into a reparative state, blood vessels in the brains of EPA-fed mice remained metabolically disrupted, and tissue recovery stalled. Over time, those animals developed pathological changes that parallel hallmarks of CTE in humans.
In an institutional summary, the MUSC team stressed that the risk signal was context-dependent. It emerged in brains subjected to repeated concussive impacts, not in uninjured tissue. The researchers pointed to populations most likely affected: football and hockey players, boxers, and others exposed to frequent head impacts over months or years. For these groups, EPA appeared to push cerebrovascular metabolism away from repair and toward a state that left tissue more vulnerable to progressive damage, a pattern that could help explain why some athletes develop worsening symptoms long after retiring from competition.
Notably, the study focused on EPA specifically and did not systematically test docosahexaenoic acid, or DHA, the other major omega-3 in most fish oil products. DHA is a structural component of brain cell membranes and has its own body of neuroprotection research. Whether it behaves differently from EPA in injured brain tissue remains an open question, and one that matters because most over-the-counter capsules contain both fatty acids in varying ratios that consumers rarely check.
A separate concern: heart rhythm and stroke
The brain findings arrive alongside a different line of evidence that has quietly unsettled assumptions about fish oil’s cardiovascular safety. A large observational study published in BMJ Medicine drew on data from approximately 415,737 participants in the UK Biobank, enrolled between 2006 and 2010 and followed through 2021. Among people free of cardiovascular disease at the start, regular fish oil supplement use was associated with a hazard ratio of roughly 1.13 for atrial fibrillation and about 1.05 for stroke. The stroke association was borderline in statistical significance, and the study’s authors acknowledged that residual confounding could not be fully ruled out.
Those relative risk increases are modest at the individual level. Scaled across the tens of millions of Americans who take fish oil daily, though, even small elevations in atrial fibrillation or stroke risk carry public health weight. The findings do not prove that fish oil caused those outcomes, but they challenge the widespread assumption that the supplements are categorically safe for the heart.
It is worth noting that the UK Biobank data reflect supplement formulations and dosing habits from the mid-2000s through the 2010s. The market has since shifted toward higher-concentration EPA products, different EPA-to-DHA ratios, and algae-based alternatives. Whether newer formulations carry the same risk profile is unknown.
Where regulators stand
The U.S. Food and Drug Administration permits qualified health claims stating that EPA and DHA consumption may reduce the risk of hypertension and coronary heart disease. Those claims, established through letters issued in 2019, use carefully hedged language: the evidence is described as “supportive but not conclusive.” That phrasing is a regulatory signal that omega-3 benefits are plausible but not proven to the standard required for an authorized health claim.
The FDA has not issued updated guidance addressing either the brain injury findings from the MUSC study or the atrial fibrillation and stroke signals from the UK Biobank analysis. Its existing framework focuses on potential cardiovascular benefits and does not speak to neurological repair, arrhythmia risk, or the possibility that EPA and DHA may have divergent effects depending on a person’s medical history.
Prescription omega-3 products add another wrinkle. Icosapent ethyl, sold as Vascepa, is a purified EPA formulation approved by the FDA to reduce cardiovascular risk in certain patients with elevated triglycerides. The REDUCE-IT trial that supported its approval did show a higher rate of atrial fibrillation in the treatment group compared to placebo. The MUSC brain injury research, while conducted in mice rather than clinical patients, raises the question of whether concentrated EPA products deserve closer scrutiny in people with concussion histories, a population that overlaps with the young athletes and veterans who may also have cardiovascular risk factors.
What has not been answered yet
The most important gap is the absence of human data linking EPA supplementation to impaired brain recovery or CTE development. No prospective study has tracked omega-3 blood levels alongside CTE biomarkers or long-term neurological outcomes in contact-sport athletes, military personnel with blast exposure, or older adults prone to falls. Until that research exists, the connection between EPA and CTE in humans remains a hypothesis built on animal biology, not a demonstrated clinical fact.
Translating mouse findings to human health decisions also requires caution about dosing. The EPA levels used in the MUSC experiments may not correspond neatly to the amounts a person gets from a standard 1,000-milligram fish oil capsule, which typically contains around 180 to 300 milligrams of EPA depending on the brand. Timing matters too: whether EPA is harmful only when taken during an active window of brain repair, or whether chronic use before injury also primes tissue for worse outcomes, has not been established.
The observational nature of the UK Biobank study carries its own limitations. People who choose to take fish oil may differ from non-users in diet, income, health awareness, and underlying conditions. Statistical adjustments can reduce but never fully eliminate that kind of confounding, which means the atrial fibrillation and stroke associations should be treated as signals worth investigating, not settled conclusions.
What this means for people taking fish oil now
None of this research supports a blanket recommendation to throw out fish oil capsules. For people without a history of head injuries, the decision to continue or stop supplementation is a conversation best had with a doctor, weighed against individual cardiovascular risk, diet, and the modest nature of the observed associations.
For people with a history of repeated concussions or mild TBIs, the calculus shifts. The MUSC findings suggest that high-dose EPA supplements could, at least theoretically, interfere with the brain’s ability to repair vascular damage after injury. Athletes still active in contact sports, retired players experiencing post-concussion symptoms, and veterans with blast-related TBI histories may want to discuss their supplement regimen with a physician or sports medicine specialist before continuing.
Dietary sources of omega-3s, such as salmon, sardines, and mackerel eaten a few times per week, have not been implicated in the same way. Whole-food sources deliver omega-3s alongside protein, selenium, vitamin D, and other nutrients in amounts and ratios that differ substantially from concentrated capsules. Most major dietary guidelines, including those from the American Heart Association, continue to recommend fatty fish as part of a heart-healthy eating pattern.
The broader shift these studies represent is away from treating omega-3s as a universal good and toward a more precise understanding of who benefits, who might not, and under what circumstances a supplement assumed to be protective could work against the body’s own repair systems. That conversation is just beginning, and it will likely sharpen as researchers design the human studies needed to test what the mouse data suggest. In the meantime, the most responsible approach is not to panic or to dismiss, but to pay closer attention to the details on the label and the details in one’s own medical history.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
